Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

763 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension.
Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. Vold SD, et al. Among authors: mallick s. J Ocul Pharmacol Ther. 2008 Dec;24(6):601-5. doi: 10.1089/jop.2008.0030. J Ocul Pharmacol Ther. 2008. PMID: 19049301 Clinical Trial.
Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MV, Mallick S; Travatan Dosing Aid Study Group. Flowers B, et al. Among authors: mallick s. Clin Ther. 2006 Nov;28(11):1803-11. doi: 10.1016/j.clinthera.2006.11.001. Clin Ther. 2006. PMID: 17213000 Clinical Trial.
A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
Hughes BA, Bacharach J, Craven ER, Kaback MB, Mallick S, Landry TA, Bergamini MV. Hughes BA, et al. Among authors: mallick s. J Glaucoma. 2005 Oct;14(5):392-9. doi: 10.1097/01.ijg.0000176935.08392.14. J Glaucoma. 2005. PMID: 16148589 Clinical Trial.
Genome-wide data from medieval German Jews show that the Ashkenazi founder event pre-dated the 14th century.
Waldman S, Backenroth D, Harney É, Flohr S, Neff NC, Buckley GM, Fridman H, Akbari A, Rohland N, Mallick S, Olalde I, Cooper L, Lomes A, Lipson J, Cano Nistal J, Yu J, Barzilai N, Peter I, Atzmon G, Ostrer H, Lencz T, Maruvka YE, Lämmerhirt M, Beider A, Rutgers LV, Renson V, Prufer KM, Schiffels S, Ringbauer H, Sczech K, Carmi S, Reich D. Waldman S, et al. Among authors: mallick s. Cell. 2022 Nov 22:S0092-8674(22)01378-2. doi: 10.1016/j.cell.2022.11.002. Online ahead of print. Cell. 2022. PMID: 36455558
763 results